{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antineoplastic+Agents", "query": { "condition": "Antineoplastic Agents" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 245, "total_pages": 25, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antineoplastic+Agents&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T07:47:54.755Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02528357", "title": "GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "GSK3174998", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 141, "start_date": "2015-09-11", "completion_date": "2020-04-29", "has_results": true, "last_update_posted_date": "2021-05-18", "last_synced_at": "2026-05-22T07:47:54.755Z", "location_count": 5, "location_summary": "Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02528357" }, { "nct_id": "NCT01204801", "title": "Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Focused Microwave Thermotherapy", "type": "DEVICE" }, { "name": "Chemotherapy (control)", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Medifocus, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 238, "start_date": "2010-11", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2015-09-24", "last_synced_at": "2026-05-22T07:47:54.755Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01204801" }, { "nct_id": "NCT06790966", "title": "Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Head and Neck Cancer", "Metastatic Head and Neck Cancer", "HPV Positive Oropharyngeal Squamous Cell Carcinoma", "Neoplasms, Head and Neck", "Unresectable Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "Combination Treatment of PDS0101 and Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Pembrolizumab Monotherapy", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "PDS Biotechnology Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2025-05-30", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-05-22T07:47:54.755Z", "location_count": 28, "location_summary": "Phoenix, Arizona • Greenbrae, California • Orange, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06790966" }, { "nct_id": "NCT02784795", "title": "A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Breast Cancer", "Colon Cancer", "Cholangiocarcinoma", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "LY3039478", "type": "DRUG" }, { "name": "Taladegib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "LY3023414", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2016-11-04", "completion_date": "2020-02-13", "has_results": true, "last_update_posted_date": "2025-08-21", "last_synced_at": "2026-05-22T07:47:54.755Z", "location_count": 4, "location_summary": "Miami, Florida • Detroit, Michigan • New York, New York + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02784795" }, { "nct_id": "NCT03094169", "title": "AVID100 in Advanced Epithelial Carcinomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Triple Negative Breast Cancer", "Head and Neck Squamous Cell Carcinoma", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "AVID100 IV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Formation Biologics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2017-02-01", "completion_date": "2021-01-30", "has_results": true, "last_update_posted_date": "2025-06-11", "last_synced_at": "2026-05-22T07:47:54.755Z", "location_count": 10, "location_summary": "New Haven, Connecticut • Grand Rapids, Michigan • New York, New York + 6 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03094169" }, { "nct_id": "NCT00002153", "title": "Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma, Kaposi", "HIV Infections", "Lymphoproliferative Disorders" ], "interventions": [ { "name": "A-007", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DEKK-TEC, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 25, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-05-22T07:47:54.755Z", "location_count": 1, "location_summary": "New Orleans, Louisiana", "locations": [ { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002153" }, { "nct_id": "NCT06046274", "title": "GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Endometrial Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Acasunlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2023-10-01", "completion_date": "2028-06-01", "has_results": false, "last_update_posted_date": "2024-04-30", "last_synced_at": "2026-05-22T07:47:54.755Z", "location_count": 2, "location_summary": "Orlando, Florida • New Brunswick, New Jersey", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06046274" }, { "nct_id": "NCT06428409", "title": "A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Pancreatic Ductal Adenocarcinoma", "Biliary Tract Cancer" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Leucovorin (LV) or levoleucovorin", "type": "DRUG" }, { "name": "Rescue medication", "type": "DRUG" }, { "name": "Supportive care measures", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2024-06-20", "completion_date": "2029-10-16", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-05-22T07:47:54.755Z", "location_count": 13, "location_summary": "Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06428409" }, { "nct_id": "NCT02252159", "title": "Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "MPN (Myeloproliferative Neoplasms)" ], "interventions": [], "intervention_types": [], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2544, "start_date": "2014-07-31", "completion_date": "2019-08-03", "has_results": false, "last_update_posted_date": "2021-04-26", "last_synced_at": "2026-05-22T07:47:54.755Z", "location_count": 264, "location_summary": "Green Valley, Arizona • Safford, Arizona • Scottsdale, Arizona + 261 more", "locations": [ { "city": "Green Valley", "state": "Arizona" }, { "city": "Safford", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02252159" }, { "nct_id": "NCT02588105", "title": "Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumours" ], "interventions": [ { "name": "AZD0156", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "irinotecan", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Folinic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 84, "start_date": "2015-11-10", "completion_date": "2022-07-26", "has_results": false, "last_update_posted_date": "2022-09-19", "last_synced_at": "2026-05-22T07:47:54.755Z", "location_count": 2, "location_summary": "Aurora, Colorado • New York, New York", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02588105" } ] }